<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111318</url>
  </required_header>
  <id_info>
    <org_study_id>1245.13</org_study_id>
    <secondary_id>2009-017202-36</secondary_id>
    <nct_id>NCT01111318</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of BI 10773 50 mg Single Dose in Male and Female Subjects With Different Degrees of Liver Impairment (Child-Pugh Classification A, B and C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the effect of mild, moderate and severe hepatic
      impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral
      administration of BI 10773 as a single dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration.</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to Maximum Concentration (Tmax)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration.</time_frame>
    <description>Time from dosing to maximum concentration of empagliflozin (empa) in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant (λz)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Terminal rate constant in plasma.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Terminal half-life of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRTpo)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Mean residence time of empagliflozin (empa) in the body.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance After Extravascular Administration (CL/F)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Apparent clearance of empagliflozin (empa) in the plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Apparent volume of distribution during the terminal phase (λz).
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Empagliflozin That is Eliminated in Urine (Ae0-96)</measure>
    <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
    <description>Amount of empagliflozin (empa) that is eliminated in urine over the time interval 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Empagliflozin Excreted Unchanged in Urine (fe0-96))</measure>
    <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
    <description>Fraction of empagliflozin (empa) excreted unchanged in urine from time points 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance After Extravascular Administration (CL R)</measure>
    <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
    <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion (UGE)</measure>
    <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
    <description>Urinary glucose excretion, this endpoint was measured using Ae0-96.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Clinical Laboratory Tests and Assessment of Tolerability by the Investigator</measure>
    <time_frame>Drug administration until 4 days after drug administration or end-of-study visit, up to 19 days</time_frame>
    <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, clinical laboratory tests and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 10773</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>2 tablets BI 10773 25 mg single dose</description>
    <arm_group_label>BI 10773</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy males and females. Hepatically impaired male and female subjects. Age: 18 - 75
        years, BMI: 18-34 kg/m2 Creatinine clearance &gt;80 mL/min (except for patients with severe
        hepatic impairment, see exclusion criteria.

        Signed and dated written informed consent prior to admission to the study in accordance
        with GCP and the local legislation.

        Exclusion criteria:

        Healthy subjects (group 1)

          1. Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders as judged by the investigator.

          2. Relevant gastrointestinal tract surgery.

          3. Diseases of the central nervous system or psychiatric disorders or relevant
             neurological disorders.

          4. History of relevant orthostatic hypotension, fainting spells or blackouts; systolic
             blood pressure &lt; 100 or &gt; 160 mm Hg, diastolic blood pressure &lt; 60 or &gt; 100 mm Hg,
             pulse rate &lt; 50 or &gt; 100 1/min.

          5. Chronic or relevant acute infections.

          6. History of allergy/hypersensitivity.

          7. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial.

          8. Use within 10 days prior to administration or during the trial of drugs which might
             reasonably influence the results of the trial based on the knowledge at the time of
             protocol preparation

          9. Participation in another trial with an investigational drug within 2 months after a
             multiple dose study or within 1 month after a single dose study.

         10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day).

         11. Inability to refrain from smoking when confined to the study site on trial days.

         12. Alcohol abuse, drug abuse.

         13. Veins unsuited for iv puncture on either arm.

         14. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial).

         15. Excessive physical activities (within 48 hours prior to trial or during the trial).

         16. Any laboratory value outside the reference range that is of clinical relevance.

         17. Inability to comply with dietary regimen of study centre.

         18. Subjects not able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions.

             Hepatically impaired subjects (group 2-4):

         19. Decompensated gastrointestinal, respiratory, cardiovascular, metabolic, immunological
             or hormonal disorders.

         20. For patients with severe liver impairment (Child-Pugh C): Severe concurrent renal
             dysfunction (e.g., due to hepato-renal syndrome) and a creatinine clearance &lt;40mL/min.

         21. Relevant gastrointestinal tract surgery.

         22. Diseases of the central nervous system or psychiatric disorders or relevant
             neurological disorders.

         23. Chronic or relevant acute infections.

         24. History of allergy/hypersensitivity.

         25. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial.

         26. Use within 10 days prior to administration or during the trial of drugs which might
             reasonably influence the results of the trial based on the knowledge at the time of
             protocol preparation. Co-medication known to inhibit or induce P-glycoprotein (such as
             quinidine, cyclosporine, amiodarone) is not allowed. In dubious cases, a case by case
             decision will be made after consultation with the sponsor.

         27. Participation in another trial with an investigational drug within 2 months after a
             multiple dose study or within 1 month after a single dose study.

         28. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day).

         29. Inability to refrain from smoking when confined to the study site on trial days.

         30. Alcohol abuse, Drug abuse.

         31. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial).

         32. Excessive physical activities (within 48 hours prior to trial or during the trial).

         33. Clinically relevant laboratory abnormalities.

         34. Inability to comply with dietary regimen of study centre.

         35. Subjects not able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

             For female subjects of all groups:

         36. Pregnancy

         37. Positive pregnancy test

         38. No adequate contraception during the study and until 2 months after study completion.

         39. Lactation period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.13.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
        </group>
        <group group_id="P2">
          <title>Mild</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
        </group>
        <group group_id="P3">
          <title>Moderate</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
        </group>
        <group group_id="P4">
          <title>Severe</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
        </group>
        <group group_id="B2">
          <title>Mild</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
        </group>
        <group group_id="B3">
          <title>Moderate</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
        </group>
        <group group_id="B4">
          <title>Severe</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="9.2"/>
                    <measurement group_id="B2" value="57.0" spread="6.9"/>
                    <measurement group_id="B3" value="51.0" spread="8.5"/>
                    <measurement group_id="B4" value="53.9" spread="9.6"/>
                    <measurement group_id="B5" value="53.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10800" spread="22.6"/>
                    <measurement group_id="O2" value="13800" spread="38.6"/>
                    <measurement group_id="O3" value="16100" spread="26.2"/>
                    <measurement group_id="O4" value="19000" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as mild divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>123.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.89</ci_lower_limit>
            <ci_upper_limit>153.36</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as moderate divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>146.97</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>118.02</ci_lower_limit>
            <ci_upper_limit>183.02</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as severe divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>174.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>140.29</ci_lower_limit>
            <ci_upper_limit>217.55</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation. The 'measured values' show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1370" spread="33.9"/>
                    <measurement group_id="O2" value="1430" spread="36.8"/>
                    <measurement group_id="O3" value="1660" spread="26.4"/>
                    <measurement group_id="O4" value="1970" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as mild divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.29</ci_lower_limit>
            <ci_upper_limit>130.95</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as moderate divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>123.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.74</ci_lower_limit>
            <ci_upper_limit>155.55</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ratio calculated as severe divided by healthy</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>148.41</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>117.65</ci_lower_limit>
            <ci_upper_limit>187.23</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration.</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10700" spread="22.6"/>
                    <measurement group_id="O2" value="13700" spread="38.4"/>
                    <measurement group_id="O3" value="15800" spread="25.7"/>
                    <measurement group_id="O4" value="18600" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to Maximum Concentration (Tmax)</title>
        <description>Time from dosing to maximum concentration of empagliflozin (empa) in plasma.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration.</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to Maximum Concentration (Tmax)</title>
          <description>Time from dosing to maximum concentration of empagliflozin (empa) in plasma.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="50.1" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.50" spread="73.2" lower_limit="0.67" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" spread="64.4" lower_limit="0.67" upper_limit="2.50"/>
                    <measurement group_id="O4" value="1.50" spread="48.2" lower_limit="0.67" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant (λz)</title>
        <description>Terminal rate constant in plasma.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant (λz)</title>
          <description>Terminal rate constant in plasma.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0414" spread="41.6"/>
                    <measurement group_id="O2" value="0.0404" spread="23.5"/>
                    <measurement group_id="O3" value="0.0454" spread="28.9"/>
                    <measurement group_id="O4" value="0.0506" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-Life (t1/2)</title>
        <description>Terminal half-life of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-Life (t1/2)</title>
          <description>Terminal half-life of empagliflozin (empa) in plasma.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="43.1"/>
                    <measurement group_id="O2" value="18.1" spread="25.9"/>
                    <measurement group_id="O3" value="17.1" spread="45.9"/>
                    <measurement group_id="O4" value="17.7" spread="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRTpo)</title>
        <description>Mean residence time of empagliflozin (empa) in the body.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRTpo)</title>
          <description>Mean residence time of empagliflozin (empa) in the body.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="31.3"/>
                    <measurement group_id="O2" value="14.4" spread="22.9"/>
                    <measurement group_id="O3" value="15.5" spread="37.2"/>
                    <measurement group_id="O4" value="15.7" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance After Extravascular Administration (CL/F)</title>
        <description>Apparent clearance of empagliflozin (empa) in the plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance After Extravascular Administration (CL/F)</title>
          <description>Apparent clearance of empagliflozin (empa) in the plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="23.9"/>
                    <measurement group_id="O2" value="150" spread="34.4"/>
                    <measurement group_id="O3" value="124" spread="30.7"/>
                    <measurement group_id="O4" value="103" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</title>
        <description>Apparent volume of distribution during the terminal phase (λz).
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F)</title>
          <description>Apparent volume of distribution during the terminal phase (λz).
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="39.5"/>
                    <measurement group_id="O2" value="237" spread="45.5"/>
                    <measurement group_id="O3" value="173" spread="35.0"/>
                    <measurement group_id="O4" value="144" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Empagliflozin That is Eliminated in Urine (Ae0-96)</title>
        <description>Amount of empagliflozin (empa) that is eliminated in urine over the time interval 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Empagliflozin That is Eliminated in Urine (Ae0-96)</title>
          <description>Amount of empagliflozin (empa) that is eliminated in urine over the time interval 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18400" spread="26.5"/>
                    <measurement group_id="O2" value="16900" spread="20.6"/>
                    <measurement group_id="O3" value="18500" spread="35.0"/>
                    <measurement group_id="O4" value="22500" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Empagliflozin Excreted Unchanged in Urine (fe0-96))</title>
        <description>Fraction of empagliflozin (empa) excreted unchanged in urine from time points 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Empagliflozin Excreted Unchanged in Urine (fe0-96))</title>
          <description>Fraction of empagliflozin (empa) excreted unchanged in urine from time points 0 to 96 hours.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>percentage of empagliflozin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="26.5"/>
                    <measurement group_id="O2" value="15.2" spread="20.6"/>
                    <measurement group_id="O3" value="16.7" spread="35.0"/>
                    <measurement group_id="O4" value="20.3" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance After Extravascular Administration (CL R)</title>
        <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h and 96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance After Extravascular Administration (CL R)</title>
          <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="30.3"/>
                    <measurement group_id="O2" value="23.7" spread="48.0"/>
                    <measurement group_id="O3" value="19.9" spread="36.8"/>
                    <measurement group_id="O4" value="21.3" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose Excretion (UGE)</title>
        <description>Urinary glucose excretion, this endpoint was measured using Ae0-96.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Pre-dose and time intervals 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h and 72-96h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion (UGE)</title>
          <description>Urinary glucose excretion, this endpoint was measured using Ae0-96.
The standard deviation is actually the coefficient of variation.</description>
          <population>Pharmacokinetic (PK) set included all subjects who were documented to have taken the investigational treatment, who provided at least one observation for at least one primary PK endpoint, without important protocol violations relevant to the evaluation of PK, provided no vomiting occurred at or before two times median tmax.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86600" spread="34.8"/>
                    <measurement group_id="O2" value="81000" spread="26.7"/>
                    <measurement group_id="O3" value="79700" spread="67.9"/>
                    <measurement group_id="O4" value="79800" spread="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Clinical Laboratory Tests and Assessment of Tolerability by the Investigator</title>
        <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, clinical laboratory tests and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AE).</description>
        <time_frame>Drug administration until 4 days after drug administration or end-of-study visit, up to 19 days</time_frame>
        <population>Treated Set (TS) included all subjects who had been dispensed study medication and were documented to have taken the investigational treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Clinical Laboratory Tests and Assessment of Tolerability by the Investigator</title>
          <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, clinical laboratory tests and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AE).</description>
          <population>Treated Set (TS) included all subjects who had been dispensed study medication and were documented to have taken the investigational treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigations: Electrocardiogram abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations: Nitrite urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Drug administration until 4 days after drug administration or end-of-study visit, up to 19 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for healthy subjects with normal liver function who matched the hepatically impaired subjects with regard to age and weight.</description>
        </group>
        <group group_id="E2">
          <title>Mild</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with mild liver impairment defined by Child-Pugh class A.</description>
        </group>
        <group group_id="E3">
          <title>Moderate</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with moderate liver impairment defined by Child-Pugh class B.</description>
        </group>
        <group group_id="E4">
          <title>Severe</title>
          <description>Single oral dose of empagliflozin (empa) 50mg (2 tablets of 25mg) following an overnight fast, for patients with severe liver impairment defined by Child-Pugh class C.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nitrite urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

